Home > Companies > Trio Medicines LTD

Trio Medicines LTD

Trio Medicines Ltd (Trio) is a small pharmaceutical company founded in 2005, wholly owned by Hammersmith Medicines Research Ltd (HMR), a CRO. Here, we focus on developing treatments for rare and unmet medical needs with the aim of improving the health and quality of life of patients around the world. Here at Trio, we are currently focused on producing effective treatments through the targeting of G-Protein Coupled Receptors (GPCRs) for a wide range of conditions. Our therapeutic expertise spans inflammatory, respiratory and cardiovascular conditions, as well as gastric neuroendocrine tumours (an orphan disease).

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

Drug Discovery And Communal Trial

3rd International Pharmaceutical Conference and Expo

80TH FIP WORLD CONGRESS OF PHARMACY AND PHARMACEUTICAL SCIENCES

3rd European Congress on Pharmaceutical Science And Research

Pharma Manufacturing And Automation

Temperature Controlled Logistics And Security

Related News

BUSINESS INSIGHTS

OPTOMED SIGNS AN INDUSTRIAL PARTNERSHIP WITH A FRENCH AI COMPANY OPHTAI

Optomed Oyj | March 21, 2022

Optomed and a French artificial intelligence company OphtAI have signed a commercial collaboration agreement, where both parties sell OphtAI artificial intelligence for screening of most common eye diseases together with Optomed Aurora handheld cameras as a complete solution for eye screening. The agreement is focusing mostly on European countries and Canada, where OphtAI has a strong presence. OphtAI offers artificial intelligence for detection of diabetic retinopathy, glaucoma a...

BUSINESS INSIGHTS

CLINICAL RESEARCH AND DRUG DEVELOPMENT ACCELERATED VIA ANALYTICS

SAS | June 22, 2022

Bringing life-changing therapies to market requires pharmaceutical companies to efficiently design and run clinical trials, gather and analyze massive amounts of data, and manage a complicated regulatory review process. SAS, a leader in clinical research analytics, delivers powerful technologies to support the life sciences industry – including machine learning, AI and analytics for IoT – through the SAS® Life Science Analytics Framework on Azure. The advanced anal...

PHARMACY MARKET

INSILICO MEDICINE ANNOUNCED STRATEGIC COLLABORATION WITH EQRX

Insilico Medicine | March 25, 2022

A clinical-stage end-to-end artificial intelligence driven drug discovery firm, Insilico Medicine announced the formation of a strategic partnership with EQRx, a company dedicated to creating and delivering novel medications to patients at much-reduced costs. The cooperation will use Insilico's Pharma.AI technology to accelerate the design and creation of de novo small molecules and EQRx's clinical development and commercialization experience. In addition, EQRx and Insilic...

PHARMACY MARKET

ATARA BIOTHERAPEUTICS AND PIERRE FABRE ENTER STRATEGIC COLLABORATION TO COMMERCIALIZE TABELECLEUCEL (TAB-CEL®)

Atara Biotherapeutics, Inc. | October 04, 2021

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will receive an upfront payment of USD 45 million, and...

BUSINESS INSIGHTS